A biopharmaceutical firm dedicated to developing a novel class of RNA treatments known as Antibody Oligonucleotide Conjugates (AOCsTM), Avidity Biosciences, Inc., today reported its advancements and plans for a game-changing year in 2025.
These significant expected milestones include completing three potentially registrational programs, submitting a Biologics License Application (BLA) for delpacibart zotadirsen (del-zota) for individuals with Duchenne muscular dystrophy mutations amenable to exon 44 skipping (DMD44), getting ready for several product launches in DMD44, myotonic dystrophy type 1 (DM1), and facioscapulohumeral muscular dystrophy (FSHD), and establishing a completely integrated, international business to support an expanding AOC pipeline in precision cardiology and neuromuscular diseases.
